Analyst Price Target is $24.00
▲ +666.77% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Ocuphire Pharma in the last 3 months. The average price target is $24.00, with a high forecast of $26.00 and a low forecast of $22.00. The average price target represents a 666.77% upside from the last price of $3.13.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in Ocuphire Pharma. This Buy consensus rating has held steady for over two years.
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.